Free circulating tumour DNA in patients with peritoneal metastases of colorectal origin and HIPEC therapy; LIBEC trial - a feasibility study

Free circulating tumour DNA in patients with peritoneal metastases of colorectal origin and HIPEC therapy; LIBEC trial - a feasibility study - LIBEC trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43017

Enrollment

Registered

2016-08-17

Start date

2016-08-29

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal metastases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Orally and written informed consent - Age 18 years and older - Elective cytoreductive surgery followed by HIPEC - Peritoneal metastases only - Regular preoperative work-up

Exclusion criteria

Exclusion criteria: - Patients who are legally or mentally incapable or unable to give informed consent - Patients younger than 18 years - Presence of liver metastases on CT-scan - Presence of pulmonary metastases on CT-scan - Anxiety for vena puncture

Design outcomes

Primary

Measure	Time frame
Plasma levels of ctDNA preoperatively and postoperatively -qualitative: is mutated ctDNA detectable yes or no? -quantitative: the ratio between the number of mutated ctDNA reads to the total number of ctDNA reads	—

Secondary

Measure	Time frame
Patient characteristics Tumour characteristics Descriptives only.	—

Countries

Netherlands

Outcome results